February 4th 2023
Treating Clostridioides difficile infection is complicated in patients coinfected with COVID-19. However, a new study suggests a significant benefit of fecal microbiota transplant (FMT) in these coinfected patients.
January 16th 2023
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
September 22nd 2022The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
Read More